FDA Approves Gene Therapy for Dystrophic Epidermolysis Bullosa, Targeting Large and Chronic Wounds

The Food and Drug Administration (FDA) approved a gene therapy for dystrophic epidermolysis bullosa (DEB). This is the first treatment of its kind for this condition. Clinical data indicated the gene therapy is effective in treating large and chronic wounds associated with DEB. Dystrophic epidermolysis bullosa is a genetic skin disorder which causes the skin to be very fragile and to blister easily. The gene therapy offers a new approach to manage this challenging condition.

Newsflash | Powered by GeneOnline AI
Date: May 2, 2025

Author

Mark Chiang